Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.

In the ≥65 years subgroup, statistically significant improvements from baseline in trough FVC were observed with FF/VI versus placebo at Days 2, 7, 14, 28, and 56, with a numerical trend in favor of FF/VI at Days 84, 112, 140, and 168 ( Supplementary Figure 2B ), and the end of the study (45 mL; p=0.334) ( Table 4 ).

also in 1,012 other papers